HIV AIDS and pregnancy: Difference between revisions

Jump to navigation Jump to search
Line 36: Line 36:
==Antepartum Care==
==Antepartum Care==
===NIH Recommendations===
===NIH Recommendations===
Monitoring of the Woman and Fetus during Pregnancy
'''Monitoring of the Woman and Fetus during Pregnancy'''
*CD4 cell count should be monitored at the initial antenatal visit ('''AI''') and at least every 3 months during pregnancy ('''BIII'''). Monitoring of CD4 count may be performed every 6 months in patients on antiretroviral treatment (ART) for more than 2–3 years who are adherent to therapy, clinically stable, and have sustained viral suppression ('''BIII''').


==Related Chapters==
==Related Chapters==

Revision as of 18:06, 11 June 2012

Sexually transmitted diseases Main Page

AIDS Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating AIDS from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

HIV Opportunistic Infections

HIV Coinfections

HIV and Pregnancy

HIV Infection in Infants

Diagnosis

Diagnostic Study of Choice

AIDS Case Definition

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Nutrition
Drug Resistance

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

HIV Vaccine

Case Studies

Case #1

HIV AIDS and pregnancy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of HIV AIDS and pregnancy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on HIV AIDS and pregnancy

CDC on HIV AIDS and pregnancy

HIV AIDS and pregnancy in the news

Blogs on HIV AIDS and pregnancy

Directions to Hospitals Treating AIDS

Risk calculators and risk factors for HIV AIDS and pregnancy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editors-in-Chief: Ujjwal Rastogi, M.B.B.S. [2]

Overivew

About 120,000 to 160,000 women in the United States are infected with HIV. Nearly one out of four of these women are unaware of their disease, which puts them at high risk of passing the virus to their babies. Mother-to-child transmission is the most common way children become infected with HIV. Nearly all AIDS cases in U.S. children are because of mother-to-child transmission.

Epidemiology

According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), 19.2 million women are living with HIV/AIDS throughout the world. In many countries, the rate of HIV infection in women is rising faster than in any other group.

Mother to child transmission

  • Not all women who have HIV will give it to their children. Without treatment or breastfeeding about 25% (1 in 4) of pregnant women with HIV will transmit the virus to their babies.
  • HIV transmission is reduced from 25% to less than 2% in women taking ART before and during birth, and if their babies are given therapy after birth. Before the current ART era, each year in the United States alone, approximately 2000 babies were infected with HIV. Despite increasing HIV prevalence, the HIV infected infants are approximately 300 per year.[1]

Prevention Challenges

  • The main challenge to preventing mother-to-child HIV transmission remains the fact that too many women don’t know they are HIV positive and they are not being routinely tested when pregnant.
  • At the same time, many women aren’t aware that the right treatment can reduce the risk of passing the virus to their babies.
  • Other important challenges include:
    • Sexual Contact with HIV-infected Men : The risk factors for women have changed. Earlier in the epidemic, more women were exposed to HIV through injection drug use. During the 1990s, women were increasingly likely to become infected through sexual contact with HIV-infected men. This is why women should know their own -- and their partners’ -- HIV status and risk factors.
    • Lack of Prenatal Care : Women at highest risk for HIV often don’t get prenatal care or don’t have access to ongoing care during their pregnancy. These women are more likely to enter the delivery room not knowing their HIV status, and have not taken the antiretroviral drugs that can treat their own disease and reduce the risk of transmitting to their infant.
    • Problems with Treatment : Many HIV-infected women and their infants still do not receive the correct drugs and other treatment or do not take the drugs properly. They may not get treatment or medical care. They may not live close to an HIV specialist who can make sure they receive proper treatment and care. Or they simply don’t have the information and resources to make decisions about their future

HIV Testing

HIV testing is recommended for all pregnant women. HIV testing is provided to pregnant women in two ways:

  1. Opt-in : In areas with opt-in testing, women may be ofered HIV testing. Women who accept testing will need to sign an HIV testing consent form.
  2. Opt-out : In areas with opt-out testing, HIV testing is automatically included as part of routine prenatal care. With opt-out testing, women must specifi­cally ask not to be tested and sign a form refusing HIV testing. The Centers for Disease Control and Prevention (CDC) recommends that opt-out testing be provided to all pregnant women.

CDC Recommendations

  • In the 2006 Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Womenin Health-Care Settings, CDC recommended the opt-out approach to testing for all adult and adolescent patients in health-care settings, including pregnant women.
  • These recommendations emphasize:
    • Universal “opt-out” HIV testing for all pregnant women early in every pregnancy;
    • A second test in the third trimester in certain geographic areas or for women who are known to be at high risk of becoming infected (e.g., injection-drug users and their sex partners, women who exchange sex for money or drugs, women who are sex partners of HIV-infected persons, and women who have had a new or more than one sex partner during this pregnancy);
    • Rapid HIV testing at labor and delivery for women without a prenatal test result; and
    • Exploration of reasons that women decline testing.

Treatment

To read about Anti-Retroviral Therapy in pregnant women, click here.

Antepartum Care

NIH Recommendations

Monitoring of the Woman and Fetus during Pregnancy

  • CD4 cell count should be monitored at the initial antenatal visit (AI) and at least every 3 months during pregnancy (BIII). Monitoring of CD4 count may be performed every 6 months in patients on antiretroviral treatment (ART) for more than 2–3 years who are adherent to therapy, clinically stable, and have sustained viral suppression (BIII).

Related Chapters

Reference

  1. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP (1998). "Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway". AIDS. 12 (14): 1735–44. PMID 9792373. Retrieved 2012-06-11. Unknown parameter |month= ignored (help)